Heidi M Munger Clary1, Rachel D Croxton2, Jonathan Allan3, James Lovato4, Gretchen Brenes5, Beverly M Snively6, Mingyu Wan7, James Kimball8, Matthew H Wong9, Cormac A O'Donovan10, Kelly Conner11, Victor Jones9, Pamela Duncan12. 1. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: hmungerc@wakehealth.edu. 2. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: croxrd13@alumni.wfu.edu. 3. Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jallan@wakehealth.edu. 4. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jlovato@wakehealth.edu. 5. Department of Internal Medicine, Section of Geriatrics, Wake Forest University, Winston-Salem, NC, USA. Electronic address: gbrenes@wakehealth.edu. 6. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: bmellen@wakehealth.edu. 7. Neuroscience Graduate Program, Wake Forest University, Winston-Salem, NC, USA. Electronic address: miwan@wakehealth.edu. 8. Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA. 9. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 10. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: odonovan@wakehealth.edu. 11. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: kconner@wakehealth.edu. 12. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: pduncan@wakehealth.edu.
Abstract
OBJECTIVE: Anxiety and depression in epilepsy are prevalent, associated with poor outcomes, underrecognized, undertreated, and thus a key area of need for treatment research. The objective of this study was to assess factors associated with research participation among epilepsy clinic patients who screened positive for anxiety or depression. This was accomplished by characterizing clinical and psychiatric factors among patients seen in an epilepsy clinic and evaluating which factors were associated with consent for potential research participation, via a combined clinical and research screening model. METHODS: In a pragmatic trial of anxiety and depression treatment in epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit were invited to opt-in (via brief electronic consent) to further eligibility assessment for a randomized treatment study. Information on psychiatric symptoms and treatment characteristics were collected for dual clinical care and research screening purposes. Cross-sectional association of demographic, clinical, and psychiatric factors with opting-in to research was analyzed by multiple logistic regression. RESULTS: Among N = 199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment. Higher depression scores and current treatment with an antidepressant were independently associated with opting-in to research (depression odds ratio (OR) = 1.13 per 1-point increase in Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score, p = 0.028, 95% confidence interval (CI): 1.01-1.26; antidepressant OR = 2.37, p = 0.041, CI: 1.04-5.41). Nearly half of the 199 individuals (43.7%) with anxiety and/or depression symptoms were already being treated with an antidepressant, and 46.7% were receiving neither antidepressant therapy nor mental health specialty care. One-quarter (24.1%) reported a past psychiatric hospitalization, yet only half of these individuals were receiving mental health specialty care. SIGNIFICANCE: Our results demonstrate a high willingness to participate in research using a brief electronic consent approach at a routine clinic visit. Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores were more willing to consider a randomized treatment study. This has implications for future study design, as individuals already on treatment or those with more severe symptoms are often excluded from traditional research designs. We also found a high burden of psychiatric disease and high prevalence of persistent symptoms despite ongoing antidepressant treatment.
OBJECTIVE:Anxiety and depression in epilepsy are prevalent, associated with poor outcomes, underrecognized, undertreated, and thus a key area of need for treatment research. The objective of this study was to assess factors associated with research participation among epilepsy clinic patients who screened positive for anxiety or depression. This was accomplished by characterizing clinical and psychiatric factors among patients seen in an epilepsy clinic and evaluating which factors were associated with consent for potential research participation, via a combined clinical and research screening model. METHODS: In a pragmatic trial of anxiety and depression treatment in epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit were invited to opt-in (via brief electronic consent) to further eligibility assessment for a randomized treatment study. Information on psychiatric symptoms and treatment characteristics were collected for dual clinical care and research screening purposes. Cross-sectional association of demographic, clinical, and psychiatric factors with opting-in to research was analyzed by multiple logistic regression. RESULTS: Among N = 199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment. Higher depression scores and current treatment with an antidepressant were independently associated with opting-in to research (depression odds ratio (OR) = 1.13 per 1-point increase in Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score, p = 0.028, 95% confidence interval (CI): 1.01-1.26; antidepressant OR = 2.37, p = 0.041, CI: 1.04-5.41). Nearly half of the 199 individuals (43.7%) with anxiety and/or depression symptoms were already being treated with an antidepressant, and 46.7% were receiving neither antidepressant therapy nor mental health specialty care. One-quarter (24.1%) reported a past psychiatric hospitalization, yet only half of these individuals were receiving mental health specialty care. SIGNIFICANCE: Our results demonstrate a high willingness to participate in research using a brief electronic consent approach at a routine clinic visit. Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores were more willing to consider a randomized treatment study. This has implications for future study design, as individuals already on treatment or those with more severe symptoms are often excluded from traditional research designs. We also found a high burden of psychiatric disease and high prevalence of persistent symptoms despite ongoing antidepressant treatment.
Authors: Frank G Gilliam; John J Barry; Bruce P Hermann; Kimford J Meador; Victoria Vahle; Andres M Kanner Journal: Lancet Neurol Date: 2006-05 Impact factor: 44.182
Authors: Frank G Gilliam; Kevin J Black; Jewell Carter; Kenneth E Freedland; Yvette I Sheline; Wei-Yann Tsai; Patrick J Lustman Journal: Ann Neurol Date: 2019-08-15 Impact factor: 10.422
Authors: Hyunmi Choi; Marla J Hamberger; Heidi Munger Clary; Rebecca Loeb; Frankline M Onchiri; Gus Baker; W Allen Hauser; John B Wong Journal: Epilepsia Date: 2014-06-05 Impact factor: 5.864
Authors: Aylin Y Reid; Amy Metcalfe; Scott B Patten; Samuel Wiebe; Sophie Macrodimitris; Nathalie Jetté Journal: Epilepsia Date: 2012-01-05 Impact factor: 5.864
Authors: Kirsten M Fiest; Scott B Patten; K Chelsea Altura; Andrew G M Bulloch; Colleen J Maxwell; Samuel Wiebe; Sophia Macrodimitris; Nathalie Jetté Journal: Epilepsy Behav Date: 2014-09-07 Impact factor: 2.937
Authors: Heidi M Munger Clary; Beverly M Snively; Umit Topaloglu; Pamela Duncan; James Kimball; Halley Alexander; Gretchen A Brenes Journal: JAMIA Open Date: 2022-10-12
Authors: Heidi M Munger Clary; Rachel D Croxton; Beverly M Snively; Gretchen A Brenes; James Lovato; Fatemeh Sadeghifar; James Kimball; Cormac O'Donovan; Kelly Conner; Esther Kim; Jonathan Allan; Pamela Duncan Journal: Epilepsy Behav Date: 2020-11-24 Impact factor: 2.937